Drug Profile
Clonidine extended release - Valerio Therapeutics/Monopar Therapeutics
Alternative Names: BA-028; Clonidine extended-release - BioAlliance Pharma; Clonidine HCl MBT; Clonidine HCl Mucoadhesive Buccal Tablet; Clonidine Lauriad; Clonidine MBT; Clonidine XR; ValidiveLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator BioAlliance Pharma
- Developer Monopar Therapeutics; Valerio Therapeutics
- Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Behavioural disorder therapies; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 27 Mar 2023 Discontinued - Phase-II/III for Stomatitis (Prevention, Chemotherapy-induced) in Puerto Rico (Buccal)
- 27 Mar 2023 Monopar Therapeutics terminates phase II/III trials in Stomatitis (Prevention, Chemotherapy-induced) in France, Germany, Puerto Rico, Spain, United States and Poland due to not meeting the pre-specified efficacy threshold(Buccal) (NCT04648020)
- 27 Mar 2023 Discontinued - Phase-I for Stomatitis (In volunteers) in United Kingdom (Buccal)